Tcelltech Inc.: Clinical Trials

4 trials sponsored by Tcelltech Inc., newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 suspended, 1 not yet recruiting, 1 recruiting. 4 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 14Suspended 2, Not yet recruiting 1, Recruiting 1

Follow Tcelltech Inc.: new trials by email

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Safety and Efficacy of DIT101 in Relapsed or Refractory Hematologic Malignancies
In Vivo CAR-T Therapy - Relapsed or Refractory Hematologic Malignancies
Phase 1Not yet recruitingTcelltech Inc.152026-04-152026-03-20
Safety and Efficacy of DIT309 in Advanced Bone and Soft Tissue Sarcomas
DIT309 cell injection - Osteosarcoma, Soft Tissue Sarcoma
Phase 1SuspendedTcelltech Inc.152025-11-062026-10-14
Phase I Study of TX103 CAR-T Cells in Participants With Advanced Solid Tumors
Anti-B7-H3 Chimeric Antigen Receptor T-Cell (CAR-T Cell) Injection/TX103 - Solid Tumors
Phase 1SuspendedTcelltech Inc.852025-10-162026-10-14
Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma.
Anti-B7-H3 Chimeric Antigen Receptor T-Cell (CAR-T Cell) Injection/TX103 - High-grade Glioma, WHO Grade Ⅳ Glioma
Phase 1RecruitingTcelltech Inc.522024-09-042026-03-24

Conditions studied

Glioma (1)  ·  Hematologic Neoplasms (1)  ·  Osteosarcoma (1)  ·  Recurrence (1)  ·  Sarcoma (1)

Interventions

Immunotherapy, Adoptive (2)  ·  Injections (2)

Countries

China (4)  ·  United States (1)

Top investigators

Gangxiong Huang, MD (4)